U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30N6O4S.C6H8O7
Molecular Weight 666.7021
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILDENAFIL CITRATE

SMILES

CCCc1c2c(c(=O)[nH]c(-c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4)n2)n(C)n1.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

InChI

InChIKey=DEIYFTQMQPDXOT-UHFFFAOYSA-N
InChI=1S/C22H30N6O4S.C6H8O7/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28;7-3(8)1-6(13,5(11)12)2-4(9)10/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI

Molecular Formula C6H8O7
Molecular Weight 192.1238
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H30N6O4S
Molecular Weight 474.5783
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic guanosine monophosphate and smooth muscle relaxation.

CNS Activity

Curator's Comment:: CNS activity was observed on rats.

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VIAGRA

Approved Use

VIAGRA is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

Launch Date

8.9095681E11
Primary
REVATIO

Approved Use

REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.

Launch Date

1.11775685E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
159 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
530 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.07 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Disc. AE: Flushing, Headache...
AEs leading to
discontinuation/dose reduction:
Flushing
Headache
Tachycardia (mild)
Sources: Page: p.2
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Disc. AE: Visual field defect...
AEs leading to
discontinuation/dose reduction:
Visual field defect
Sources: Page: p.2
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.258
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 45
Sex: M
Population Size: 1
Sources: Page: p.258
Disc. AE: Rhabdomyolysis, Visual disturbance NOS...
AEs leading to
discontinuation/dose reduction:
Rhabdomyolysis
Visual disturbance NOS
Sources: Page: p.258
80 mg 3 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources: Page: p.1278
unhealthy, 47.5
n = 135
Health Status: unhealthy
Condition: Pulmonary arterial hypertension
Age Group: 47.5
Sex: M+F
Population Size: 135
Sources: Page: p.1278
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Disc. AE: Vomiting, Blurred vision...
AEs leading to
discontinuation/dose reduction:
Vomiting (severe)
Blurred vision
Sinus tachycardia
Sources: Page: p.1
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources:
Disc. AE: Cardiomegaly, Fibrosis myocardial...
AEs leading to
discontinuation/dose reduction:
Cardiomegaly (grade 5)
Fibrosis myocardial (grade 5)
Sources:
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (0.32%)
Vomiting (0.32%)
Leg pain (0.32%)
Backache (0.32%)
Intermittent headache (0.32%)
Dyspepsia (0.32%)
Headache (0.32%)
Sources: Page: p.1400
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1403
unhealthy, 60
n = 163
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 163
Sources: Page: p.1403
Disc. AE: Headache, Flushing...
AEs leading to
discontinuation/dose reduction:
Headache (0.61%)
Flushing (0.61%)
Sources: Page: p.1403
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Disc. AE: Headache, Flushing...
AEs leading to
discontinuation/dose reduction:
Headache (0.9%)
Flushing (0.44%)
Blurred vision (0.44%)
Groin pain (1.3%)
Sources: Page: p.1401
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.1,2
unhealthy, 67
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 67
Sex: M
Population Size: 1
Sources: Page: p.1,2
Disc. AE: Acute kidney injury...
AEs leading to
discontinuation/dose reduction:
Acute kidney injury
Sources: Page: p.1,2
AEs

AEs

AESignificanceDosePopulation
Flushing Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Headache Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Tachycardia mild
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Visual field defect Disc. AE
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources: Page: p.2
healthy, 33
n = 1
Health Status: healthy
Age Group: 33
Sex: M
Population Size: 1
Sources: Page: p.2
Rhabdomyolysis Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.258
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 45
Sex: M
Population Size: 1
Sources: Page: p.258
Visual disturbance NOS Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources: Page: p.258
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 45
Sex: M
Population Size: 1
Sources: Page: p.258
Blurred vision Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Sinus tachycardia Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Vomiting severe
Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources: Page: p.1
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources: Page: p.1
Cardiomegaly grade 5
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources:
Fibrosis myocardial grade 5
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
n = 1
Health Status: healthy
Age Group: 56
Sex: M
Population Size: 1
Sources:
Backache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Dyspepsia 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Headache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Intermittent headache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Leg pain 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Nausea 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Vomiting 0.32%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1400
unhealthy, 58
n = 316
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 58
Sex: M
Population Size: 316
Sources: Page: p.1400
Flushing 0.61%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1403
unhealthy, 60
n = 163
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 163
Sources: Page: p.1403
Headache 0.61%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1403
unhealthy, 60
n = 163
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 163
Sources: Page: p.1403
Blurred vision 0.44%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Flushing 0.44%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Headache 0.9%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Groin pain 1.3%
Disc. AE
100 mg 1 times / day multiple, oral (max)
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources: Page: p.1401
unhealthy, 60
n = 225
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 60
Sex: M
Population Size: 225
Sources: Page: p.1401
Acute kidney injury Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources: Page: p.1,2
unhealthy, 67
n = 1
Health Status: unhealthy
Condition: Erectile dysfunction
Age Group: 67
Sex: M
Population Size: 1
Sources: Page: p.1,2
PubMed

PubMed

TitleDatePubMed
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.
2001
Use of sildenafil in penile implant patients.
2001
'Viagra effect' - influence of mass media on patient behavior.
2001
Safe use of sildenafil in patients with coronary artery disease.
2001 Apr
Cost-sharing for prescriptions of sildenafil and finasteride: a case study in veteran patients.
2001 Apr
Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy.
2001 Apr
Sildenafil citrate for penile hemodynamic determination: an alternative to intracavernosal agents in Doppler ultrasound evaluation of erectile dysfunction.
2001 Apr
Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil.
2001 Apr
Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction.
2001 Apr
Intracavernosal injection of sildenafil citrate: misapplication of the drug.
2001 Apr
Studies of Viagra offer some reassurance to men with concerns about cardiac effects.
2001 Apr 18
Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation.
2001 Feb
Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction.
2001 Feb
Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials.
2001 Feb
Intracerebral haemorrhage associated with sildenafil citrate.
2001 Feb
I've heard of an herbal alternative to Viagra for impotence. Does it work and is it safe?
2001 Feb
Efficacy of oral sildenafil in the treatment of erectile dysfunction in diabetic men with positive response to intracavernosal injection of alprostadil.
2001 Feb
Interposition sural nerve grafting during radical retropubic prostatectomy.
2001 Feb
Sex and the heart: what is the role of the cardiologist?
2001 Feb
Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy.
2001 Feb
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
2001 Feb
Sildenafil inhibits gastroduodenal motility.
2001 Feb
[Endocrinology 1999-2000].
2001 Feb 15
Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis?
2001 Feb 15
[Research on impotence and marketing].
2001 Feb 20
Cost-effectiveness of sildenafil.
2001 Feb 6
Cost-effectiveness of sildenafil.
2001 Feb 6
Cost-effectiveness of sildenafil.
2001 Feb 6
The role of nitric oxide in penile erection.
2001 Jan
Emergency sperm extraction for transient erectile dysfunction prior to assisted conception.
2001 Jan
Intracavernosal injection therapy. Does it still have a role in erectile dysfunction?
2001 Jan
Sexual aspects of headache. How sexual function relates to headaches and their causes and treatment.
2001 Jan
pH-mediated field-amplified sample stacking of pharmaceutical cations in high-ionic strength samples.
2001 Jan
Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians.
2001 Jan
Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis.
2001 Jan
[Prescribing of sildenafil by national insurance program physicians. What basic sexual medicine qualification is required?].
2001 Jan 11
[Erectile dysfunction in coronary heart disease. No fear about the blue pill].
2001 Jan 18
[Paths to sexual satisfaction. What will stimulate the tired man?].
2001 Jan 18
Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site.
2001 Jan 26
Identification and regulation of human PDE5A gene promoter.
2001 Jan 26
Viagra: a three-year sexual revolution and the need to recognise its role within the NHS.
2001 Mar
Initial uptake in use of sildenafil in general practice.
2001 Mar
Anterior ischemic optic neuropathy associated with viagra.
2001 Mar
Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
2001 Mar
Combination of phentolamine and L-arginine or sildenafil synergistically improves neurogenic relaxation of rabbit corpus cavernosum smooth muscle.
2001 Mar
Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium.
2001 Mar
[Side effects of sildenafil: findings from two years practical experience].
2001 Mar 17
Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.
2001 Mar 17
Narrowbore high-performance liquid chromatography for the simultaneous determination of sildenafil and its metabolite UK-103,320 in human plasma using column switching.
2001 Mar 5
Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A.
2001 May
Patents

Sample Use Guides

Erectile disfunction: For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Pulmonary arterial hypertension: 5 mg or 20 mg three times a day, 46 hours apart (oral); 2.5 mg or 10 mg three times a day administered as an intravenous bolus injection.
Route of Administration: Other
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/20590607
Human bladder samples were treated with sildenafil (10 nM–30 µM) to test the ability of the drug to inhibit contraction.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:06:25 UTC 2021
Edited
by admin
on Fri Jun 25 21:06:25 UTC 2021
Record UNII
BW9B0ZE037
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SILDENAFIL CITRATE
JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
SILDENAFIL CITRATE [USP MONOGRAPH]
Common Name English
UK-92,480-10
Code English
SILDENAFIL CITRATE [EP MONOGRAPH]
Common Name English
SILDENAFIL CITRATE [WHO-DD]
Common Name English
NSC-744009
Code English
SILDENAFIL CITRATE [VANDF]
Common Name English
NSC-758669
Code English
UK-92480-10
Code English
SILDENAFIL CITRATE [MART.]
Common Name English
SILDENAFIL CITRATE [USP-RS]
Common Name English
SILDENAFIL CITRATE [MI]
Common Name English
SILDENAFIL CITRATE [USAN]
Common Name English
REVATIO
Brand Name English
SILDENAFIL CITRATE [JAN]
Common Name English
VIAGRA
Brand Name English
1-((3-(6,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-4-METHYLPIPERAZINE CITRATE (1:1)
Systematic Name English
SILDENAFIL (AS CITRATE)
Common Name English
SILDENAFIL CITRATE [ORANGE BOOK]
Common Name English
PIPERAZINE, 1-((3-(6,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-4-METHYL-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (1:1)
Systematic Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS VIAGRA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
EU-Orphan Drug EU/3/03/178
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
NCI_THESAURUS C2127
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
Code System Code Type Description
DRUG BANK
DBSALT000347
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
EPA CompTox
171599-83-0
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL192
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
PUBCHEM
135413523
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
RXCUI
221161
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C26670
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
USP_CATALOG
1612561
Created by admin on Fri Jun 25 21:06:27 UTC 2021 , Edited by admin on Fri Jun 25 21:06:27 UTC 2021
PRIMARY USP-RS
MERCK INDEX
M9898
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY Merck Index
CAS
171599-83-0
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
FDA UNII
BW9B0ZE037
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
EVMPD
SUB04386MIG
Created by admin on Fri Jun 25 21:06:26 UTC 2021 , Edited by admin on Fri Jun 25 21:06:26 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
any zone due to impurity E is not more intense than the principal zone in the chromatogram obtained with reference solution (b) (0.1 per cent)
CHROMATOGRAPHIC PURITY (TLC)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY